New research links wildfire smoke to lasting respiratory decline and skin flares, months after exposure ends.
News|Articles|March 19, 2026
AAD 2026 Preview: Late Breaking Data to Watch
Author(s)Tim Smith
Fact checked by: Ryan Livingston
This preview highlights key data to watch out for during the 2026 American Academy of Dermatology (AAD) meeting in Denver, Colorado.
Advertisement
Advertisement
The
Related to this article
The FDA has granted Priority Review to dersimelagon for EPP and XLP, setting a PDUFA date for late February 2027 as LEO Pharma completes its acquisition from Tanabe Pharma.
Neal Bhatia, MD, weighs the newly approved Ameluz PDT regimen for sBCC against Mohs surgery, citing its 66% composite response rate.
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
In this Q&A, Leon Kircik, MD, discusses challenging watch-and-wait for molluscum contagiosum with berdazimer gel, 10.3%, at LEADderm 2026.
In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.
FDA accepts Cogent's bezuclastinib NDA for advanced systemic mastocytosis, backed by APEX trial data showing durable, high-rate responses.
Oberlin outlines what dermatologists should weigh, beyond APEX's radiographic data, when selecting a biologic for a patient with psoriatic arthritis.
Advertisement
Advertisement